Roivant Sciences Ltd.
ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
$38.66−0.30 (-0.78%)
Close on Nov 20, 2026Market cap $27.92BP/E –Yield –
Roivant Sciences Arbutus Biopharma by Quarter
Arbutus Biopharma — Investment Fair Value (Level 1) ($M)
Roivant Sciences Arbutus Biopharma: $186M in Q2 FY2026, up 5.3% from a year earlier.
Latest, Q2 FY2026
186
Period ended Sep 30, 2026 (CQ3 2026)
Change on a year earlier
+5.3%
176 in Q2 FY2025
History
18 quarters
Since Q4 FY2021
Sources
17
Documents cited below
Where the Q2 FY2026 figure comes from
Source: Form 10-Q (filed 2026-11-09) ↗
Reported in Form 10-K / 10-Q (XBRL).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Arbutus Biopharma — Investment Fair Value (Level 1) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 FY2026CQ3 2026 | Sep 30, 2026 | 186 | +5.3% | Form 10-Q (filed 2026-11-09) ↗ |
| Q1 FY2026CQ2 2026 | Jun 30, 2026 | 187 | +55.4% | Form 10-Q (filed 2026-08-06) ↗ |
| Q4 FY2025CQ1 2026 | Mar 31, 2026 | 175 | +28.9% | Form 10-Q (filed 2026-11-09) ↗ |
| Q3 FY2025CQ4 2025 | Dec 31, 2025 | 187 | +47.2% | Form 10-Q (filed 2026-02-06) ↗ |
| Q2 FY2025CQ3 2025 | Sep 30, 2025 | 176 | +17.9% | Form 10-Q (filed 2025-11-10) ↗ |
| Q1 FY2025CQ2 2025 | Jun 30, 2025 | 120 | 0.0% | Form 10-Q (filed 2025-08-11) ↗ |
| Q4 FY2024CQ1 2025 | Mar 31, 2025 | 136 | +35.3% | Form 10-K (filed 2026-05-20) ↗ |
| Q3 FY2024CQ4 2024 | Dec 31, 2024 | 127 | +30.8% | Form 10-Q (filed 2025-02-10) ↗ |
| Q2 FY2024CQ3 2024 | Sep 30, 2024 | 150 | +89.6% | Form 10-Q (filed 2024-11-12) ↗ |
| Q1 FY2024CQ2 2024 | Jun 30, 2024 | 120 | +34.4% | Form 10-Q (filed 2024-08-09) ↗ |
| Q4 FY2023CQ1 2024 | Mar 31, 2024 | 100 | -14.9% | Form 10-K (filed 2025-05-29) ↗ |
| Q3 FY2023CQ4 2023 | Dec 31, 2023 | 97.1 | +7.3% | Form 10-Q (filed 2024-02-13) ↗ |
| Q2 FY2023CQ3 2023 | Sep 30, 2023 | 78.9 | +6.3% | Form 10-Q (filed 2023-11-13) ↗ |
| Q1 FY2023CQ2 2023 | Jun 30, 2023 | 89.3 | – | Form 10-Q (filed 2023-08-14) ↗ |
| Q4 FY2022CQ1 2023 | Mar 31, 2023 | 118 | +1.6% | Form 10-K (filed 2024-05-30) ↗ |
| Q3 FY2022CQ4 2022 | Dec 31, 2022 | 90.5 | – | Form 10-Q (filed 2023-02-13) ↗ |
| Q2 FY2022CQ3 2022 | Sep 30, 2022 | 74.2 | – | Form 10-Q (filed 2022-11-14) ↗ |
| Q4 FY2021CQ1 2022 | Mar 31, 2022 | 116 | – | Form 10-K (filed 2023-06-28) ↗ |
Cite this data
StockData. (2026). Roivant Sciences Arbutus Biopharma ($M), quarterly Q4 FY2021–Q2 FY2026 [Data set]. Compiled from Roivant Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/roiv/kpis/fv-arbutus
See every metric in the Roivant Sciences KPI table. Data updated Nov 16, 2026.
See a number that looks wrong?